Korro Bio, Inc. is a biotechnology company focused on advancing RNA-targeted therapies to treat various genetic diseases
The company develops innovative solutions leveraging its proprietary technologies aimed at delivering precise and effective treatments through the modulation of RNA. Korro Bio is dedicated to addressing unmet medical needs by harnessing the potential of RNA biology and transforming therapeutic approaches for patients suffering from serious health conditions. Through its research and development efforts, the company strives to pioneer advances in the field of precision medicine.
Industry veterans John Maraganore, Ph.D., and Rachel Meyers, Ph.D., to provide strategic guidance on the company’s RNA Actuating platform to develop a new class of RNA medicines that upregulate protein coding genes
The European Central Bank cut interest rates for the second time in about three months prior the FOMC's interest rate announcement, European stocks may benefit.
William Blair initiates coverage on Korro Bio highlighting its innovative RNA editing platform, ADAR-based OPERA. The analyst rates the stock Outperform, noting its potential in treating alpha-1 antitrypsin deficiency.
H.C. Wainwright initiated coverage on Korro Bio Inc (NASDAQKRRO), a biotech company developing genetic medicines focused on editing ribonucleic acid (RNA) to treat various diseases.
